At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open Label Phase 2 Single Agent Study of LCL-161 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis, Questionnaire Administration, and 1 other intervention for Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase and 2 related conditions. Completed, enrolled 50 participants across 1 site.
Detailed Summary
This phase II trial studies how well second mitochondrial-derived activator of caspases (SMAC) mimetic LCL161 (LCL161) works in treating patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocytosis myelofibrosis. SMAC mimetic LCL161 may help control the growth of abnormal cells by promoting apoptosis (programmed cell death).
Study Details
Timeline
Interventions
Correlative studies
Ancillary studies
Given PO